Vasogen Added to the TSE 300 Composite Index
Sep 26, 2000
Toronto, Ontario
Vasogen Inc. (TSE:VAS; AMEX:MEW) today announced that it has been selected to be included on the TSE 300 Composite Index under the Biotechnology/Pharmaceuticals section of the Consumer Products sub-index. This inclusion becomes effective after the close of trading on the Toronto Stock Exchange (TSE) today.
The TSE 300 Composite Index, introduced in 1977, is a broad
market indicator that represents 300 of the largest
publicly-traded companies in Canada. The TSE regularly reviews the Indices and follows strict criteria for inclusion and maintenance policies to ensure that the Indices continually provide key information for investors.
"We are very pleased to be included in the select group of
companies which comprise the TSE 300 Index," commented David
Elsley, President and CEO of Vasogen. "With five indications in clinical trials, a solid financial position and a strong research pipeline to support future growth, Vasogen remains committed to enhancing shareholder value through the commercial development of its proprietary immune modulation therapy for the treatment of a number of autoimmune and inflammatory diseases."
Over the next three quarters, Vasogen expects to report results from five ongoing clinical trials targeting the treatment and prevention of psoriasis, peripheral vascular disease, congestive heart failure, ischemia/reperfusion injury, and graft-versus-host disease.
Vasogen is focused on developing immune modulation therapies to advance the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies are designed to target fundamental disease-causing events, providing safe, effective treatment.
INVESTOR CONTACT
Glenn Neumann
Investor Relations
(905) 569-9065
investor@vasogen.com
Vasogen Inc.
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1
tel: (905) 569-2265 fax: (905) 569-9231
www.vasogen.com
Statements contained in this press release, including those
pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. |
